跳至主要内容
临床试验/NCT01512563
NCT01512563已完成不适用

Clinical Trial Comparing Patency and Safety of the Paclitaxel Eluting Covered Metallic Biliary Stent(Niti-S Mira-Cover Biliary Stent ) to the Common Covered Metallic Biliary Stent(Niti-S Biliary Stent)

Taewoong Medical Co., Ltd.4 个研究点 分布在 1 个国家目标入组 106 人开始时间: 2007年2月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
106
试验地点
4
主要终点
Accumulative Patency Rate

研究概览

简要总结

Paclitaxel covered metal biliary stent extents their patency rate comparing to the Common Covered Metallic Biliary Stent.

详细描述

Paclitaxel covered metal biliary stent(Mira-Cover Biliary Stent) extents their patency rate comparing to the Common Covered Metallic Biliary Stent(Niti-S Biliary Stent.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Single (Participant)

入排标准

年龄范围
19 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient who is inoperable and/or unresectable cases of pancreatic cancer and/or biliary cancer with mid or distal CBD invasion
  • Among patient of a.,Patient who previously had surgical biliary drainage of plastic stent have eligibility

排除标准

  • Patient who have life expectancy under 3 months
  • Patient who have severe metastasis of Liver or whole body
  • Patient who previously had surgical biliary drainage

结局指标

主要结局

Accumulative Patency Rate

时间窗: 6 month

次要结局

  • Complications(6 months)
  • Accumulative Survival Rate(6 months)
  • Possibility of Other Treatment after Obstruction(6 months)

研究者

发起方
Taewoong Medical Co., Ltd.
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验